Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers
Summary
"The Tachyon team are enabling new frontiers in targeted oncology by developing cancer therapies that address fundamental drivers of tumorigenesis," commented Heath Lukatch, Ph.D., Managing Director of Red Tree Venture Capital. "We look forward to supporting the team as they work towards transforming the treatment paradigms for advanced and metastatic solid tumors. "The start of our first clinical trial for TACH101, our lead program, is a significant milestone for the company as we strive to bring promising new therapeutics to patients who are fighting advanced cancers," continued Dr. Perabo. Dr. Staffords discovery teams have been responsible for the discovery of three FDA-approved drugs Votrient (pazopanib), Nesina (alogliptin), and Byfavo (remimazolam) and several others currently in clinical trials.Tachyon Therapeutics, Inc. develops first-in-class therapeutics against novel targets from previously unexplored cancer dysregulation pathways to propel new options for the treatment of advanced cancers. Tachyon operates with a dedicated internal core development team and a virtual external network of expertise to achieve one goal advance our programs with speed, innovation, quality and scientific integrity.